A survey of the incidence of skin infections in patients with atopic dermatitis treated with topical medications

A survey of the incidence of skin infections in patients with atopic dermatitis treated with topical medications -A cohort study using detailed medical fee data from health insurance associations and national health insurance associations- - A survey of the incidence of skin infections in patients with atopic dermatitis treated with topical medications -A cohort study using detailed medical fee data from health insurance associations and national health insurance associations-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055543

Enrollment

6000

Registered

2024-10-01

Start date

2024-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Cases in which atopic dermatitis (ICD10 code: L20: Atopic dermatitis) was diagnosed during the inclusion period, and the subject drug (difamilast ointment, topical steroids (by rank), non-steroids (tacrolimus ointment, delgocitinib ointment)) was started in the same month 2.Cases of patients under 75 years of age 3.Cases for which observation is possible for 180 days before the index date (cases for which there is an entry in the insured person register)

Exclusion criteria

Exclusion criteria: 1.Cases where any skin infection (diseases defined as skin infections in 7.2.1) has occurred within 180 days prior to the start of drug administration Cases where any skin infection (diseases defined as skin infections in 7.2.1) has occurred within 180 days prior to the start of drug administration 2.Patients diagnosed with diabetes (E10-E14) within 180 days prior to the start of administration 3.Patients using immunosuppressants (oral and injectable) within 180 days prior to the start of administration

Design outcomes

Primary

Measure	Time frame
Skin infections (folliculitis, acne, impetigo, herpes infection, Kaposi's varicelliform eruption, tinea, warts, candidiasis, cellulitis, erysipelas, molluscum contagiosum, carbuncle, furuncle)	—

Countries

Japan

Contacts

Public ContactMiyuki Matsukawa

Otsuka Pharmaceutical Co., Ltd. Medical Affairs

Matsukawa.Miyuki@otsuka.jp06-6943-7722

Outcome results